WE-Sita 50 Tablet contains Sitagliptin 50 mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin works by enhancing the incretin system, which increases insulin release from pancreatic beta cells and decreases glucagon secretion from alpha cells in a glucose-dependent manner, thereby improving glycemic control. WE-Sita 50 is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The medication is generally well tolerated, with a low risk of hypoglycemia when used alone. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections. Caution is advised in patients with renal impairment, and dose adjustments may be necessary based on renal function. WE-Sita 50 should be used under medical supervision, with regular monitoring of blood glucose levels and renal function to optimize therapeutic outcomes and minimize potential adverse effects. It is not indicated for type 1 diabetes or diabetic ketoacidosis. Patient adherence to prescribed lifestyle modifications remains critical for effective diabetes management.